Clinical trials: Chemotherapeutic Toxicity
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Chemotherapeutic Toxicity
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
Anthracycline-paclitaxel sequential combination therapy is the standard regimen for perioperative chemotherapy in breast cancer. The strategy of perioperative chemotherapy is based on breast cancer subtype, i.e.
- Trial name
- NCT05302336
- Testing
- Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cancer, Chemotherapy-induced Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function
As cancer survival rates have been increased due to technological developments and early detection strategies, there has been been a growing need to assess the effect of long-term complications and adverse effects upon patients'…
- Conditions
- Cancer, Chemotherapy-induced Peripheral Neuropathy, Chemotherapeutic Toxicity, Breast Cancer
- Trial name
- NCT04799080
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Izmir Bakircay University
Chemotherapeutic Agent Toxicity, Neurotoxicity
Acute Pain Caused by Paclitaxel in Patients With Cancer
RATIONALE: Gathering information over time from patients receiving paclitaxel for cancer may help doctors learn more about pain caused by paclitaxel and plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00860041
- Testing
- pain questionnaires
- Where
- 279 sites in United States
- Volunteers
- 306 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapeutic Agent Toxicity, Neutropenia
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00770172
- Testing
- filgrastim
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Francois Baclesse
Solid Carcinoma, 5-Fluorouracil Toxicity
Prevention of Chest Pain in Chemo-treated Cancer Patients
This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment…
- Conditions
- Solid Carcinoma, 5-Fluorouracil Toxicity, Cardiotoxicity, Chemotherapeutic Toxicity
- Trial name
- CATCH (NCT03486340)
- Testing
- Cardiologic assessment
- Where
- Denmark
- Volunteers
- 218 people
- Sponsor
- Vejle Hospital
Acute Lymphoid Leukemia, Minimal Residual Disease
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be…
- Conditions
- Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality, Chemotherapeutic Toxicity
- Trial name
- BRALLA (NCT05959720)
- Testing
- Prednisone, Vincristin, Daunorubicin
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Frailty, Chemotherapeutic Toxicity
Tolerance of Anti-Cancer Therapy in the Elderly
This is a multicentre observational study evaluating frailty and tolerance of chemotherapy in the elderly.
- Trial name
- TOASTIE (NCT05251922)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Myocardial Fibrosis, Myocardial Injury
Myocardial Perfusion and Fibrosis in Cancer Survivors
This is a cross-sectional pilot study. The investigators seek to obtain early information pertaining to the relationship between measurements of myocardial perfusion reserve and myocardial fibrosis after receipt of…
- Conditions
- Myocardial Fibrosis, Myocardial Injury, Chemotherapeutic Toxicity
- Trial name
- NCT03191461
- Testing
- Adenosine stress test MRI
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Breast Cancer, Chemotherapeutic Toxicity
Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients
investigating the potential effect of Coenzyme Q10 in ameliorating and preventing the development of paclitaxel chemotherapeutic toxicity in breast cancer patients
- Trial name
- NCT06570811
- Testing
- Coenzyme Q10 200mg twice daily
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Damanhour University
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Chemotherapeutic Toxicity, Malignant Tumor
Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy
This is an open , multicenter, interventional clinical trial to conform the role of of miR-122 a real-time detection biomarker of drug-induced liver injury by chemotherapy.
- Conditions
- Chemotherapeutic Toxicity, Malignant Tumor, Liver Injury
- Trial name
- NCT03039062
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Cardiovascular Complication, Chemotherapeutic Toxicity
At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure
The goal of this clinical trial is to explore the impact that an at-home cardio-oncology rehabilitation (CORE) may have on short-term cardiovascular fitness and psychosocial wellness in pediatric cancer survivors.
- Trial name
- NCT06826534
- Testing
- Cardio-oncology rehabilitation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Los Angeles
Chemotherapeutic Agent Toxicity, Neurotoxicity
Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Peripheral Neuropathy
- Trial name
- NCT00952848
- Testing
- questionnaire administration, Sensory Neuropathy Scale instrument, Quality of Life instrument
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Dermatologic Complications, Palmar-plantar Erythrodysesthesia
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with…
- Conditions
- Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00486213
- Testing
- pyridoxine hydrochloride
- Where
- Singapore
- Volunteers
- 210 people
- Sponsor
- National Cancer Centre, Singapore
Colon Cancer, Breast Cancer
Improving Food Pleasure and Intake of Oncology Patients Receiving Chemotherapy
The global cancer burden is estimated to have risen to 18.1 million new cases in 2018 (WHO), with a trend of ongoing growth. This very frequent illness exerts tremendous physical, emotional and financial strain on individuals…
- Conditions
- Colon Cancer, Breast Cancer, Chemotherapeutic Toxicity
- Trial name
- NCT04495387
- Testing
- Chemotherapy
- Volunteers
- 100 people
- Sponsor
- University of Florence
Chemotherapeutic Toxicity
Machine Learning to Predict Acute Care During Cancer Therapy
The objective of this study is to apply a validated machine-learning based model (SHIELD-RT, NCT04277650) to a cohort of patients undergoing systemic therapy as outpatient cancer treatment to generate an automatic system for the…
- Trial name
- Chemo-SHIELD (NCT05122247)
- Testing
- Machine learning algorithm
- Where
- United States
- Volunteers
- 12,000 people
- Sponsor
- Duke University
Adverse Event, Cancer, Breast
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
The aim of this study is to determine whether the use of breast cancer patients' own electronic reporting of side effects to chemotherapy in a treatment setting has an impact on the handling of side effects and on the number of…
- Conditions
- Adverse Event, Cancer, Breast, Chemotherapeutic Toxicity, Patient Outcomes Assessments
- Trial name
- NCT02996201
- Testing
- Completion of PRO-CTCAE items before consultation
- Volunteers
- 700 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chemotherapeutic Agent Toxicity, Sarcoma
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.
- Conditions
- Chemotherapeutic Agent Toxicity, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00514345
- Testing
- gene expression analysis, polymorphism analysis, management of therapy complications
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 300 people
- Sponsor
- Children's Cancer and Leukaemia Group
Cancer, Chemotherapeutic Toxicity
Serial PET MPI in Patients Undergoing Cancer Treatment
This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.
- Conditions
- Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease, Coronary Microvascular Disease
- Trial name
- NCT05913999
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles